Abstracts tagged "Scleroderma"

Abstract Number: 1854 • ACR Convergence 2021
Disease Characteristics and Social Determinants in African Americans with Systemic Sclerosis: A Single Center Experience
Sarah Compton, DeAnna Baker Frost, Richard Silver and Diane Kamen, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune disease categorized on the basis of skin involvement as either limited or diffuse cutaneous SSc, the latter…
Abstract Number: 1370 • ACR Convergence 2021
Complement Factor D and Factor H Represent Disease and Severity Biomarkers for Systemic Sclerosis Associated Pulmonary Arterial Hypertension (SSc-PAH)
Roberta G Marangoni¹, Changyong Feng¹, Ashley Frazer-Abel², Stephen Tomlinson³, Amy Wielgosz¹, Katie Lutz⁴, Michael Pauciulo⁴, William Nichols⁴, V. Michael Holers⁵, Christopher Ritchlin⁶, R James White III¹ and Benjamin Korman¹, ¹University of Rochester, Rochester, NY, ²University of Colorado Denver, Colorado, CO, ³Medical University of South Carolina, Charleston, SC, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Colorado, Denver, CO, ⁶Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Pulmonary arterial hypertension (PAH) is a severe vascular complication of systemic sclerosis (SSc) and a major cause of mortality. Despite significant advances in the…
Abstract Number: 1856 • ACR Convergence 2021
Serum IFN Score Predicts Long Term Outcome in Limited Cutaneous SSc
Ranjitha Karanth¹, Giuseppina Abignano², Vishal Kakkar², Rebecca Ross², Christopher Denton³ and Francesco Del Galdo², ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, LTHT, Leeds, United Kingdom, ²University of Leeds, Leeds, United Kingdom, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, United Kingdom
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) carries a highly variable prognosis and to date there are no stratification tools to predict clinical outcomes. Evidence suggests…
Abstract Number: 1371 • ACR Convergence 2021
Symptom Management in Systemic Sclerosis: A Pilot Study of a Web-based Intervention Using Peer-Health Coaches
Susan Murphy¹, Yen Chen², Mary Alore², Sheri Hicks² and Dinesh Khanna², ¹University of Michigan, Grosse Ile, MI, ²University of Michigan, Ann Arbor, MI
Background/Purpose: People with systemic sclerosis (SSc) have a high burden of chronic symptoms that have dramatic effects on function and quality of life. Fatigue, along…
Abstract Number: L09 • ACR Convergence 2020
A Phase 2a Randomized, Double-blind, Placebo-controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis (NOVESA)
Dinesh Khanna¹, Christopher Denton², Daniel Furst³, Maureen Mayes⁴, Marco Matucci-Cerinic⁵, Vanessa Smith⁶, Dick de Vries⁷, Liesbeth Deberdt⁸, Pieter‑Jan Stiers⁸, Niyati Prasad⁸ and Sohail Ahmed⁹, ¹University of Michigan, Ann Arbor, MI, ²Royal Free Hospital, University College London, London, United Kingdom, ³David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴University of Texas Health Science Center at Houston, Houston, TX, ⁵Università degli Studi di Firenze, Firenze, Italy, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Galapagos BV, Leiden, Netherlands, ⁸Galapagos NV, Mechelen, Belgium, ⁹Ahmed Science Medicine, Basel, Switzerland
Background/Purpose: There is a high unmet need for systemic sclerosis (SSc) treatments. Ziritaxestat (ziri; GLPG1690) is an autotaxin inhibitor with a novel mechanism of action.…
Abstract Number: 0390 • ACR Convergence 2020
Baseline Characteristics of Systemic Sclerosis (SSc) Patients with Restrictive Lung Disease in a Multi-Center United States Based Longitudinal Registry
Flavia Castelino¹, John VanBuren², Emily Startup², Shervin Assassi³, Elana Bernstein⁴, Lorinda Chung⁵, Chase Correia⁶, Luke Evnin⁷, Tracy Frech⁸, Jessica Gordon⁹, Faye Hant¹⁰, Laura Hummers¹¹, Dinesh Khanna¹², Nora Sandorfi¹³, Ami Shah¹⁴, Victoria Shanmugam¹⁵ and Virginia Steen¹⁶, ¹Massachusetts General Hospital/Harvard Medical School, Boston, MA, ²University of Utah, Salt Lake City, UT, ³University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, ⁴Columbia University, New York, NY, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA, ⁶Northwestern University, Chicago, IL, ⁷Scleroderma Research Foundation, Brisbane, CA, ⁸University of Utah and Salt Lake Veterans Affair Medical Center, Salt Lake City, UT, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Medical University of South Carolina, Charleston, SC, ¹¹Johns Hopkins Univerisity, Ellicott City, MD, ¹²University of Michigan, Ann Arbor, MI, ¹³University of Pennsylvania, Philadelphia, PA, ¹⁴Johns Hopkins University School of Medicine, Ellicott City, MD, ¹⁵The George Washington University, Washington, DC, ¹⁶Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of death in SSc. Several international observational studies have evaluated characteristics of ILD in their SSc patient…
Abstract Number: 0928 • ACR Convergence 2020
Systemic Sclerosis Progression and Pregnancy: A Hopeful Message from the Canadian Scleroderma Registry Database
Siobhan Deshauer¹, Mats Junek², Maggie Larche³ and Karen Beattie³, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ³McMaster University, Hamilton, ON, Canada
Background/Purpose: There is limited guidance for women with systemic sclerosis (SSc) in making decisions about pregnancy and informing them about their disease post-partum. Peripartum maternal…
Abstract Number: 1388 • ACR Convergence 2020
A Systematic Assessment of Demographics, Clinical and Serological Features Associated with Colonic Hypomotility in Systemic Sclerosis
Jenice Cheah¹, Jamie Perin², Elizabeth Volkmann³, Laura Hummers⁴, Fredrick Wigley⁵ and Zsuzsanna McMahan⁶, ¹JHUSOM, Baltimore, ²JHUSPH, Baltimore, ³University of California, Los Angeles, Los Angeles, CA, ⁴Johns Hopkins Univerisity, Ellicott City, MD, ⁵Johns Hopkins University School of Medicine, Baltimore, MD, ⁶Johns Hopkins University, Baltimore
Background/Purpose: Colonic dysmotility affects up to 50% of patients with systemic sclerosis (SSc). While some patients have mild colonic disease, others experience severe complications, such…
Abstract Number: 0393 • ACR Convergence 2020
Agreement Between Physician Evaluation and the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS)
Boyang Zheng¹, Mianbo Wang², Kerry McKenna³, Lee Shapiro⁴, Robert Spiera⁵, Richard Silver⁶, Mary Ellen Csuka⁷, Frank van den Hoogen⁸, David Robinson⁹, Laura Hummers¹⁰, Thomas Krieg¹¹, Francesco Del Galdo¹², Niall Jones¹³, Nader Khalidi¹⁴, Alessandra Vacca¹⁵, Jessica Gordon¹⁶, John Pauling¹⁷ and Murray Baron¹⁸, ¹McGill University, Montreal, Canada, ²Lady Davis institute for Medical Research, Montreal, QC, Canada, ³Jewish General Hospital, McGill University, Montreal, Canada, ⁴Albany Medical College, Stillwater, NY, ⁵Division of Rheumatology, Hospital for Special Surgery, New York, New York, USA, New York, NY, ⁶Medical University of South Carolina, Charleston, ⁷Medical college of Wisconsin, Milwaukee, WI, ⁸Sint Maartenskliniek, Nijmegen, Netherlands, ⁹University of Manitoba, Winnipeg, MB, Canada, ¹⁰Johns Hopkins Univerisity, Ellicott City, MD, ¹¹University of Cologne, Cologne, Germany, ¹²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom, ¹³Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹⁴McMaster University, Hamilton, ON, Canada, ¹⁵University Hospital of Cagliari, Monserrato, Italy, ¹⁶Hospital for Special Surgery, New York, NY, ¹⁷Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ¹⁸Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Diffuse cutaneous Systemic Sclerosis (dcSSc) is a morbid disease involving the skin and internal organs. The American College of Rheumatology has provisionally approved a…
Abstract Number: 1055 • ACR Convergence 2020
Myositis and Systemic Sclerosis Spectrum IPAF Patients Are More Likely to Respond Favorably to Immunosuppression
Erin Wilfong¹, Gabriel Schroeder¹, April Barnado¹, Steven Lord¹, Narender Annapureddy¹, Rosemarie Dudenhofer¹ and Leslie J. Crofford¹, ¹Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Classification criteria for interstitial pneumonia with autoimmune features (IPAF) were introduced in 2015 to identify interstitial lung disease (ILD) patients who might benefit from…
Abstract Number: 1393 • ACR Convergence 2020
Systemic Sclerosis: Subclinical Aterosclerosis and Morbimortality
Miriam Retuerto¹, Jose Luis Rosales², Maria Martin¹, Beatriz Joven¹ and Patricia E Carreira¹, ¹Hospital universitario 12 de octubre, Madrid, Spain, ²Hospiten Rambla, Santa Cruz de Tenerife, Spain
Background/Purpose: Rheumatic diseases are associated with accelerated atherosclerosis, and an increase in cardiovascular morbidity and mortality. This process is mediated by classic cardiovascular risk factors…
Abstract Number: 0394 • ACR Convergence 2020
Prevalence of a Diagnosis of Osteopenia/Osteoporosis Amongst Patients with Systemic Sclerosis and Identification of Associated Clinical Factors
Guanying Wang¹, Diane Mar², Joy Wu³, Julia Simard⁴, Rita Popat¹ and Lorinda Chung⁵, ¹Department of Epidemiology & Population Health, Stanford University School of Medicine, Palo Alto, CA, ²Stanford Department of Immunology/Rheumatology, Palo Alto, CA, ³Department of Medicine, Division of Endocrinology, Stanford University School of Medicine, Palo Alto, CA, ⁴Stanford Medicine, Stanford, CA, ⁵Stanford University School of Medicine and Palo Alto VA Health Care System, Palo Alto, CA
Background/Purpose: This study aims to determine the prevalence of a diagnosis of osteopenia/osteoporosis (OP) in systemic sclerosis (SSc) patients and to identify the clinical and…
Abstract Number: 1064 • ACR Convergence 2020
Anti-SMN Autoantibodies Are Associated with Systemic Sclerosis Small Bowel Involvement in anti-U1RNP Positive Autoimmune Myositis
Caroline Vo¹, Océane Landon-Cardinal², Alexandra Albert³, Alain Meyer⁴, Valérie Leclair⁵, Josiane Bourré-Tessier², Sabrina Hoa², Eric Rich¹, Jean-Richard Goulet¹, Benjamin Ellezam⁶, Maude Bouchard-Marmen⁷, Martial Koenig⁸, Geneviève Gyger⁵, Ira N. Targoff⁹, Marie Hudson⁵, Minoru Satoh¹⁰, Marvin Fritzler¹¹, Yves Troyanov¹² and Jean-Luc Senécal², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ³Division of Rheumatology, Centre Hospitalier de l’Université Laval, Québec, QC, Canada, ⁴Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁵Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ⁶Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada, ⁷Division of Rheumatology, Centre Hospitalier de l’Université Laval, Department of Medicine, Université Laval, Québec, QC, Canada, ⁸Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Department of Medicine, Université de Montréal, Montréal, QC, Canada, ⁹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada
Background/Purpose: The survival of motor neuron (SMN)/gemin proteins are components of a multifunctional protein complex that plays an essential role in RNA metabolism. SMN is…
Abstract Number: 1398 • ACR Convergence 2020
The Isolated Nucleolar Pattern ANA Antibody in a Systemic Sclerosis Patient Cohort
Sabrina Elliott¹, Duncan Moore² and Virginia Steen², ¹MedStar Georgetown Hospital, Alexandria, VA, ²Division of Rheumatology, Department of Medicine, MedStar Georgetown University Hospital, Washington, DC
Background/Purpose: Systemic Sclerosis (SSc) patients with an isolated nucleolar patterned ANA (NUC ANA) make up about 15% of the SSc population, although the specific nucleolar…
Abstract Number: 0397 • ACR Convergence 2020
Assessing Adherence to Screening of Systemic Sclerosis-Related Lung Disease
Matthew Herrmann¹ and Zineb Aouhab¹, ¹Loyola University Medical Center, Maywood, IL
Background/Purpose: Feared complications of systemic sclerosis (SSc) affect the pulmonary system, with pulmonary hypertension and interstitial lung disease being common causes of mortality. Baseline and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].